

FIG. 1



Home | Documents | Settings | Help | Log Out

Dashboard

Solution Sets

Library

Personal

Manage Categories


All
Clinical Outcomes
Utilization Outcomes
Strategic Outcomes

Solution Set Reports


Refresh

- ▶ AMI Ace Inhibitors
- ▶ AMI Aspirin Early Use
- ▶ AMI Aspirin Upon Discharge
- ▶ AMI Beta Blocker Early Use
- ▶ AMI Beta Blocker Upon Discharge
- ▶ AMI Calcium Channel Blockers
- ▶ AMI Calcium Channel Blockers by Attend
- ▶ AMI Order Set Analysis
- ▶ Diabetes Type 2 Ambulatory Order Set An
- ▶ Diabetes Type 2 Nephropathy Assessme
- ▶ Diabetes Type 2 Nephropathy Assessme
- ▶ Diabetes Type 2 Nephropathy Pts Not Sci


AMI ALOS 2002 YTD




AMI Mortality Rate 2002 YTD



Cardiology Net Income (Loss) 2002 YTD



JCAHO AMI Core Measures 2002 YTD



Statistics 2002 YTD




FIG. 2




FIG. 3



Home | Documents | Settings | Help | Log Out

Dashboard

Solution Set Viewer

CERNER
POWERINSIGHT

Welcome, BL4571!

Solution Sets

Library

Personal


Manage Categories

All
Clinical Outcomes
Utilization Outcomes
Strategic Outcomes

AMI - Calcium Channel Blockers by Attending Physician

For the Year Ending 2002

Attending Physician	# of AMI Pts	% of Pts Rec 80 mg/day or More of Short-Acting Nitroglycerine	Mortality Rate
Wilson, Matt	234	0%	3%
Daescrner, Robert	213	5%	6%
Wilson, Randy	185	6%	4%
Waker, Zack	155	6%	7%
aan, Kathy	143	7%	8%
Burth, Judi	135		
Sather, Beth	122		
Farrinond, Steve	120		
Packler, Susan	103		
Jackson, Tyone	100		
ngold, Drian	90		
Wilson, Susan	81		
arison, Ron	70		
Sayers, Jules	64		
Desmond, Jane	41		
Hagen John	41		
Ficktinger Andrew	33		
Travis Mary	26		
Henning, Ian	22		
Askerscn, Sara	17		
2000		20%	10%




Solution Set Reports

Refresh

- AMI Ace Inhibitors
- AMI Aspirin Early Use
- AMI Aspirin Upon Discharge
- AMI Beta Blocker Early Use
- AMI Beta Blocker Upon Discharge
- AMI Calcium Channel Blockers
- AMI Calcium Channel Blockers by Att nd
- AMI Order Set Analysis
- Diabetes Type 2 Ambulatory Order Set Ai
- Diabetes Type 2 Nephropathy Assessme
- Diabetes Type 2 Nephropathy Assessme
- Diabetes Type 2 Nephropathy Pts Not Sci

FIG. 4



If all eligible patients at your institution who are not currently receiving care in accordance with the guideline were to receive the stated intervention, then the potential benefits that could be achieved for this group of patients are as follows:

Potential number of lives saved by avoiding the use of short-acting nifedipine in patients with AMI	12 <input checked="" type="checkbox"/>
Potential cost savings in 1 year arising from the avoidance of short-acting nifedipine use in patients with AMI (\$)	157,920 <input checked="" type="checkbox"/>

FIG. 6

